Advice Pool - Finance

The Sharpe Ratio is a formula used to measure risk/return. The ratio describes the amount of extra return received for the extra volatility of a more risky a

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

sset. The higher the Sharpe Ratio, the greater returns are for each unit of risk. The Sharpe Ratio is calculated by subtracting the risk free rate or return

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

from the return of the portfolio and then dividing by the portfolio's standard deviation. By using the Sharpe Ratio, investors can theoretically compare risk

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

adjusted returns of investments or portfolios that have different returns and risk levels. The higher the ratio is the better.

Formula S=E

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

(R-Rf)/Standard Deviation

The numerator of the ratio is the expected return that an asset is expected to provide above the risk free rate.

The denominator

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

is the portfolio's standard deviation. Standard deviation is the square root of the variance of the portfolio. Possible outcomes fall within standard deviati

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

ons. Possible returns are most likely within one standard deviation. Two standard deviations covers about 95% of observations. Three standard deviations acco

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

unt for over 99% of observations.

Sharpe Ratio Problems or Limitations The Sharpe Ratio is a very useful statistic for portfolio or investm

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

ent comparison. However, like many aspects of finance and investing the ratio has problems and limitations.

The Sharpe Ratio uses standard deviation as a me

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

asure of volatility. Some argue, however, that standard deviation is not a proper measure of volatility. Standard deviation is only a rough proxy for a non d

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

efinite concepts such as risk.

The Portfolio return component of the Sharpe Ratio assumes or requires that returns are normally distributed. However, the ma

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

rkets are subject to many abnormalities, such as fatter tails, that can skew this normal distribution, thus limiting the Sharpe Ratio's accuracy.

Future mar

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

ket uncertainty also limits the Sharpe Ratio. Historic Sharpe Ratios are calculated using returns and standard deviations over previous periods. While histor

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

ic data can provide a good general idea of trends and values, past performance is no guarantee of future results. Forward-looking Sharpe Ratios are based on

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

projections which also are limited by future uncertainty.

Sharpe Ratio calculation needs to be adjusted for portfolio analysis. Using the Sharpe Ratio to di

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

rectly compare two investments as the basis for adding one to a portfolio is not entirely correct. The Sharpe Ratio may be inaccurate if one or more of the i

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

nvestments is highly correlated with other investments in the portfolio. The solution to this problem is to construct different Sharpe Ratios for different p

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

ortfolios.

Conclusion The Sharpe Ratio is an important statistic for measuring risk adjusted returns, comparing alternative portfolios, and

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

comparing similar investments. Although the ratio has limitations, the Sharpe Ratio is still a very important tool for investment comparison and analysis.

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

To learn more about finance and investing, visit the Sharpe Investing blog.

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.advicepool.org.ua/article/101491/advicepool-Sharpe-Ratio.html">Sharpe Ratio</a>

BB link (for phorums):
[url=http://www.advicepool.org.ua/article/101491/advicepool-Sharpe-Ratio.html]Sharpe Ratio[/url]

For women, it has been a long struggle for self-realization as an exemplary mother and male companion, and respected businessperson. Traditionally, women did not receive appropriate support from the family, which acknowledged and rewarded only the traditional gender roles. Women in business were lonely and misunderstood, often disapproved in their intentions to prove themselves equally qualified and worthy among men.

As the title says, here are ten quick and valuable sales tips you can use to grow your business.

To qualify for any small business start up loans you will need to go through the same basic steps. First you will need to request a loan application package. Second you will need to read through the information to learn about what documents, reports, and materials will be needed. Next you will need to put together a business plan or prospectus. If you have never put one of these together before you may want to hire a financial services professional to help you with the business plan and with the various financial reports that the lender will need to see.

Tags

Links

Advice Pool - Sharpe Ratio

Related Articles: